PMID- 23469940
OWN - NLM
STAT- MEDLINE
DCOM- 20140224
LR  - 20211021
IS  - 1399-5448 (Electronic)
IS  - 1399-543X (Linking)
VI  - 14
IP  - 5
DP  - 2013 Aug
TI  - Glucose tolerance and beta-cell function in islet autoantibody-positive children 
      recruited to a secondary prevention study.
PG  - 341-9
LID - 10.1111/pedi.12023 [doi]
AB  - AIMS: Children with type 1 diabetes (T1D) risk and islet autoantibodies are 
      recruited to a secondary prevention study. The aims were to determine metabolic 
      control in relation to human leukocyte antigen (HLA) genetic risk and islet 
      autoantibodies in prepubertal children. METHODS: In 47 healthy children with GADA 
      and at least one additional islet autoantibody, intravenous glucose tolerance 
      test (IvGTT) and oral glucose tolerance test (OGTT) were performed 8-65 d apart. 
      Hemoglobin A1c, plasma glucose as well as serum insulin and C-peptide were 
      determined at fasting and during IvGTT and OGTT. RESULTS: All children aged 
      median 5.1 (4.0-9.2) yr had autoantibodies to two to six of the beta-cell 
      antigens GAD65, insulin, IA-2, and the three amino acid position 325 variants of 
      the ZnT8 transporter. In total, 20/47 children showed impaired glucose 
      metabolism. Decreased (</= 30 muU/mL insulin) first-phase insulin response (FPIR) 
      was found in 14/20 children while 11/20 had impaired glucose tolerance in the 
      OGTT. Five children had both impaired glucose tolerance and FPIR </= 30 muU/mL 
      insulin. Number and levels of autoantibodies were not associated with glucose 
      metabolism, except for an increased frequency (p = 0.03) and level (p = 0.01) of 
      ZnT8QA in children with impaired glucose metabolism. Among the children with 
      impaired glucose metabolism, 13/20 had HLA-DQ2/8, compared to 9/27 of the 
      children with normal glucose metabolism (p = 0.03). CONCLUSION: Secondary 
      prevention studies in children with islet autoantibodies are complicated by 
      variability in baseline glucose metabolism. Evaluation of metabolic control with 
      both IvGTT and OGTT is critical and should be taken into account before 
      randomization. All currently available autoantibody tests should be analyzed, 
      including ZnT8QA.
CI  - (c) 2013 John Wiley & Sons A/S.
FAU - Andersson, Cecilia
AU  - Andersson C
AD  - Department of Clinical Sciences, Lund University/CRC, Skane University Hospital 
      SUS, Malmo, Sweden. Cecilia_K.Andersson@med.lu.se
FAU - Carlsson, Annelie
AU  - Carlsson A
FAU - Cilio, Corrado
AU  - Cilio C
FAU - Cedervall, Elisabeth
AU  - Cedervall E
FAU - Ivarsson, Sten-Anders
AU  - Ivarsson SA
FAU - Jonsdottir, Berglind
AU  - Jonsdottir B
FAU - Jonsson, Bjorn
AU  - Jonsson B
FAU - Larsson, Karin
AU  - Larsson K
FAU - Neiderud, Jan
AU  - Neiderud J
FAU - Lernmark, Ake
AU  - Lernmark A
FAU - Elding Larsson, Helena
AU  - Elding Larsson H
CN  - DiAPREV-IT Study Group
LA  - eng
GR  - R01 DK026190/DK/NIDDK NIH HHS/United States
GR  - DK26190/DK/NIDDK NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20130308
PL  - Denmark
TA  - Pediatr Diabetes
JT  - Pediatric diabetes
JID - 100939345
RN  - 0 (Autoantibodies)
RN  - 0 (Cation Transport Proteins)
RN  - 0 (HLA Antigens)
RN  - 0 (HLA-DQ Antigens)
RN  - 0 (HLA-DQ2 antigen)
RN  - 0 (Insulin)
RN  - 0 (SLC30A8 protein, human)
RN  - 0 (Zinc Transporter 8)
RN  - EC 3.1.3.48 (PTPRN protein, human)
RN  - EC 3.1.3.48 (Receptor-Like Protein Tyrosine Phosphatases, Class 8)
RN  - EC 4.1.1.15 (Glutamate Decarboxylase)
RN  - EC 4.1.1.15 (glutamate decarboxylase 2)
RN  - IY9XDZ35W2 (Glucose)
SB  - IM
MH  - Autoantibodies/*blood
MH  - Cation Transport Proteins/genetics/immunology
MH  - Child
MH  - Child, Preschool
MH  - Diabetes Mellitus, Type 1/immunology/*prevention & control
MH  - Female
MH  - Glucose/metabolism
MH  - Glucose Intolerance/*immunology
MH  - Glucose Tolerance Test
MH  - Glutamate Decarboxylase/*immunology
MH  - HLA Antigens/immunology
MH  - HLA-DQ Antigens/immunology
MH  - Humans
MH  - Insulin/immunology
MH  - Insulin-Secreting Cells/*immunology
MH  - Male
MH  - Receptor-Like Protein Tyrosine Phosphatases, Class 8/immunology
MH  - Zinc Transporter 8
OTO - NOTNLM
OT  - FPIR
OT  - GAD65 autoantibodies
OT  - HLA genotype
OT  - IA-2 autoantibodies
OT  - T1D
OT  - ZnT8
OT  - diabetes mellitus
OT  - glucose tolerance
OT  - insulin autoantibodies
OT  - secondary prevention
OT  - zinc transporter
FIR - Larsson, Helena E
IR  - Larsson HE
FIR - Lernmark, Ake
IR  - Lernmark A
FIR - Nilsson, Caroline
IR  - Nilsson C
FIR - Hansson, Gertie
IR  - Hansson G
FIR - Arvastsson, Jeanette
IR  - Arvastsson J
FIR - Brundin, Charlotte
IR  - Brundin C
FIR - Hemmendal, Jennifer
IR  - Hemmendal J
FIR - Jonsson, Ida
IR  - Jonsson I
FIR - Nilsson, Anita
IR  - Nilsson A
FIR - Mestan, Zeliha
IR  - Mestan Z
FIR - Shalouie, Aliram
IR  - Shalouie A
FIR - Wigheden, Ingrid
IR  - Wigheden I
FIR - Winqvist, Annika
IR  - Winqvist A
FIR - Andersson, Cecilia
IR  - Andersson C
FIR - Meineche, Susanne Bach
IR  - Meineche SB
FIR - Carlsson, Annelie
IR  - Carlsson A
FIR - Cederwall, Elisabeth
IR  - Cederwall E
FIR - Cilio, Corrado
IR  - Cilio C
FIR - Edgren, Joakim
IR  - Edgren J
FIR - Ivarsson, Sten
IR  - Ivarsson S
FIR - Jonsdottir, Berglind
IR  - Jonsdottir B
FIR - Jonsson, Bjorn
IR  - Jonsson B
FIR - Larsson, Karin
IR  - Larsson K
FIR - Lindberg, Bengt
IR  - Lindberg B
FIR - Neiderud, Jan
IR  - Neiderud J
FIR - Olsson, Ann
IR  - Olsson A
FIR - Persson, Lars Ake
IR  - Persson LA
FIR - Ortqvist, Eva
IR  - Ortqvist E
FIR - Gard, Thomas
IR  - Gard T
EDAT- 2013/03/09 06:00
MHDA- 2014/02/25 06:00
CRDT- 2013/03/09 06:00
PHST- 2012/09/21 00:00 [received]
PHST- 2012/12/06 00:00 [revised]
PHST- 2013/01/04 00:00 [accepted]
PHST- 2013/03/09 06:00 [entrez]
PHST- 2013/03/09 06:00 [pubmed]
PHST- 2014/02/25 06:00 [medline]
AID - 10.1111/pedi.12023 [doi]
PST - ppublish
SO  - Pediatr Diabetes. 2013 Aug;14(5):341-9. doi: 10.1111/pedi.12023. Epub 2013 Mar 8.